News - Markets & Marketing, Benlysta

Filter

Popular Filters

EU5 rheumatologits rate Rituxan and Benlysta for Lupus

12-08-2013

Rheumatologists in the top European nations ( EU5) countries (France, Germany, Italy, Spain, UK) give…

Anti-Arthritics/RheumaticsBenlystaBiogen IdecBristol-Myers SquibbEuropeGlaxoSmithKlineMarkets & MarketingOrenciaPharmaceuticalRituxanRoche

Lupus therapeutics boast blockbuster hopefuls as R&D continues, says GlobalData

24-06-2013

Lupus therapeutics are lacking, and patients with moderate forms of the disease are greatly underserved,…

BenlystaBiotechnologyBristol-Myers SquibbepratuzumabGlaxoSmithKlineImmunologicalsMarkets & MarketingOrenciaPharmaceuticalRare diseasesResearchUCB

Benlysta will be lupus market leader in 2021 with sales of more than $1.7 billion, says DR

25-10-2012

In the systemic lupus erythematosus (SLE) drug market, Human Genome Sciences/GlaxoSmithKline's (LSE:…

BenlystaBiotechnologyGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRare diseases

Benlysta continues to penetrate lupus market one year post-launch; report

08-05-2012

More than two-thirds of surveyed rheumatologists have initiated trial of GlaxoSmithKline (LSE: GSK) and…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceuticalRare diseases

Human Genome Sciences’ Benlysta sales disappoint

11-01-2012

US biotech firm Human Genome Sciences (Nasdaq: HGSI) president and chief executive Thomas Watkins yesterday…

BenlystaBiotechnologyFinancialHuman Genome SciencesMarkets & MarketingRare diseasesraxibacumab

Benlysta gaining bigger US market share

13-12-2011

Over half of surveyed US rheumatologists surveyed by Decision Resources unit BioTrends have initiated…

Anti-Arthritics/RheumaticsBenlystaBiotechnologyGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingNorth AmericaPharmaceuticalRare diseases

Systemic lupus erythematosus drug market to grow to $1.6 billion in 2018

10-11-2011

The global systemic lupus erythematosus (SLE) therapeutics market in the seven leading countries ( the…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineGlobalHuman Genome SciencesMarkets & MarketingPharmaceutical

Benlysta to drive lupus drug market to $2.1 billion in 2020

26-10-2011

Driven primarily by the launch and uptake of Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineMarkets & MarketingPharmaceuticalRare diseases

Remicade, Humira and Enbrel made up 40% of the immunomodulators market in 2010; report

23-08-2011

Tumor necrosis factor (TNF) inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis…

Anti-Arthritics/RheumaticsBenlystaEnbrelGilenyaHumiraMarkets & MarketingNeurologicalPharmaceuticalRemicade

Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends

07-08-2011

Rheumatologists are maintaining enthusiasm for Human Genome Sciences (Nasdaq: HGSI) and GlaxoSmithKline’s…

Anti-Arthritics/RheumaticsBenlystaGlaxoSmithKlineHuman Genome SciencesMarkets & MarketingPharmaceutical

Back to top